Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource UtilizatioRelease Date:Research Inflammation & Immunology China Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for VitiligoRelease Date:Research Inflammation & Immunology China Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)Release Date:Partner: American Society for Clinical Pathology (ASCP)Quality Improvement Oncology USA Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factorsRelease Date:Quality Improvement, Research Oncology Italy Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-TRelease Date:Research Oncology USA Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada Title Grant Type Focus Area Country Application Due Date Acute Lymphoblastic Leukemia Peer-to-Peer Education & SupportRelease Date:Education Oncology USA PARP-inhibitor Combination Treatments in Prostate CancerRelease Date:Education Oncology USA Optimizing Patient Access to CDK 4/6 Inhibitors in the Armamentarium Against Metastatic Breast CancerRelease Date:Education Oncology USA Understanding healthcare disparities in Atopic Dermatitis and Alopecia Areata patientsRelease Date:Quality Improvement Inflammation & Immunology All ADVANCE: Global Awards for Advancing Chronic Pain ResearchRelease Date:Research Internal Medicine All Enhancing the Understanding of Health Maintenance in the Management of IBDRelease Date:Education Inflammation & Immunology USA Outpatient Management of COVID-19Release Date:Education Hospital Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Luxembourg, Macedonia, The Former Yugoslav, Malta, Moldova, Republic of, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia (Slovak Republic), Slovenia, Spain, Sweden, Switzerland, Tajikistan, Turkey, Turkmenistan, Ukraine, United Kingdom, Uzbekistan Emerging Therapies in Alopecia Areata for Dermatologists - United StatesRelease Date:Education Inflammation & Immunology USA Virtual Programs for Rheumatology EducationRelease Date:Education Inflammation & Immunology USA 2021/2022 Global NASH ASPIRERelease Date:Research Internal Medicine All Addressing Knowledge Gaps in Alopecia Areata and Atopic Dermatitis (Global (excluding the US)Release Date:Education Inflammation & Immunology All 2021/2022 Global Obesity ASPIRERelease Date:Research Internal Medicine All